| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyBiologicalProcess | regulation of defense response | SELE USP18 WASHC4 ASH1L PPARG NR1D1 BCR MEF2C PTPRC PPP6C TRIM62 TLR1 MMRN2 C3 PLCG2 USP15 KLRD1 XRCC6 NLRP13 | 6.19e-06 | 1006 | 121 | 19 | GO:0031347 |
| GeneOntologyBiologicalProcess | negative regulation of microglial cell activation | 1.08e-05 | 8 | 121 | 3 | GO:1903979 | |
| GeneOntologyBiologicalProcess | neuroinflammatory response | 2.89e-05 | 101 | 121 | 6 | GO:0150076 | |
| GeneOntologyBiologicalProcess | positive regulation of endocytosis | 3.76e-05 | 213 | 121 | 8 | GO:0045807 | |
| GeneOntologyBiologicalProcess | regulation of immune response | USP18 TRAF2 WASHC4 PPARG NR1D1 BCR CLEC12A MEF2C SVEP1 PTPRC PPP6C TRIM62 TLR1 C3 PLCG2 USP15 KLRD1 XRCC6 | 6.18e-05 | 1085 | 121 | 18 | GO:0050776 |
| GeneOntologyBiologicalProcess | regulation of response to external stimulus | SELE USP18 WASHC4 ASH1L PPARG NR1D1 BCR PTPRC PPP6C TRIM62 TLR1 AIPL1 MMRN2 ADAMTS18 C3 PLCG2 USP15 KLRD1 XRCC6 NLRP13 | 7.84e-05 | 1316 | 121 | 20 | GO:0032101 |
| GeneOntologyBiologicalProcess | regulation of behavior | 1.09e-04 | 128 | 121 | 6 | GO:0050795 | |
| GeneOntologyBiologicalProcess | positive regulation of phagocytosis, engulfment | 1.51e-04 | 18 | 121 | 3 | GO:0060100 | |
| GeneOntologyBiologicalProcess | positive regulation of membrane invagination | 1.51e-04 | 18 | 121 | 3 | GO:1905155 | |
| GeneOntologyBiologicalProcess | regulation of neuroinflammatory response | 1.52e-04 | 46 | 121 | 4 | GO:0150077 | |
| GeneOntologyBiologicalProcess | positive regulation of defense response | WASHC4 NR1D1 MEF2C PPP6C TRIM62 TLR1 MMRN2 C3 PLCG2 USP15 KLRD1 XRCC6 | 1.82e-04 | 589 | 121 | 12 | GO:0031349 |
| GeneOntologyBiologicalProcess | negative regulation of neuroinflammatory response | 2.09e-04 | 20 | 121 | 3 | GO:0150079 | |
| GeneOntologyBiologicalProcess | negative regulation of macrophage activation | 2.09e-04 | 20 | 121 | 3 | GO:0043031 | |
| GeneOntologyBiologicalProcess | regulation of innate immune response | USP18 WASHC4 PPARG NR1D1 PPP6C TRIM62 TLR1 PLCG2 USP15 KLRD1 XRCC6 | 2.43e-04 | 519 | 121 | 11 | GO:0045088 |
| GeneOntologyBiologicalProcess | positive regulation of phagocytosis | 2.95e-04 | 99 | 121 | 5 | GO:0050766 | |
| GeneOntologyBiologicalProcess | activation of immune response | WASHC4 NR1D1 MEF2C SVEP1 PTPRC PPP6C TLR1 C3 PLCG2 USP15 KLRD1 XRCC6 | 3.03e-04 | 623 | 121 | 12 | GO:0002253 |
| GeneOntologyBiologicalProcess | antifungal innate immune response | 3.20e-04 | 23 | 121 | 3 | GO:0061760 | |
| GeneOntologyBiologicalProcess | regulation of microglial cell activation | 3.20e-04 | 23 | 121 | 3 | GO:1903978 | |
| GeneOntologyBiologicalProcess | response to gamma radiation | 3.27e-04 | 56 | 121 | 4 | GO:0010332 | |
| GeneOntologyBiologicalProcess | positive regulation of response to biotic stimulus | WASHC4 NR1D1 PPP6C TRIM62 TLR1 MMRN2 PLCG2 USP15 KLRD1 XRCC6 | 3.29e-04 | 451 | 121 | 10 | GO:0002833 |
| GeneOntologyBiologicalProcess | regulation of antifungal innate immune response | 3.37e-04 | 5 | 121 | 2 | GO:1905034 | |
| GeneOntologyBiologicalProcess | regulation of phagocytosis, engulfment | 3.64e-04 | 24 | 121 | 3 | GO:0060099 | |
| GeneOntologyBiologicalProcess | microglial cell activation | 4.00e-04 | 59 | 121 | 4 | GO:0001774 | |
| GeneOntologyBiologicalProcess | regulation of response to biotic stimulus | USP18 WASHC4 PPARG NR1D1 PPP6C TRIM62 TLR1 MMRN2 PLCG2 USP15 KLRD1 XRCC6 | 4.03e-04 | 643 | 121 | 12 | GO:0002831 |
| GeneOntologyBiologicalProcess | regulation of membrane invagination | 4.12e-04 | 25 | 121 | 3 | GO:1905153 | |
| GeneOntologyBiologicalProcess | positive regulation of immune response | TRAF2 WASHC4 NR1D1 MEF2C SVEP1 PTPRC PPP6C TRIM62 TLR1 C3 PLCG2 USP15 KLRD1 XRCC6 | 4.38e-04 | 845 | 121 | 14 | GO:0050778 |
| GeneOntologyBiologicalProcess | regulation of endocytosis | 4.85e-04 | 389 | 121 | 9 | GO:0030100 | |
| GeneOntologyBiologicalProcess | uterus morphogenesis | 5.04e-04 | 6 | 121 | 2 | GO:0061038 | |
| GeneOntologyBiologicalProcess | leukocyte activation involved in inflammatory response | 5.14e-04 | 63 | 121 | 4 | GO:0002269 | |
| GeneOntologyBiologicalProcess | negative regulation of immune response | 5.29e-04 | 239 | 121 | 7 | GO:0050777 | |
| GeneOntologyCellularComponent | Dsl1/NZR complex | 1.01e-04 | 3 | 122 | 2 | GO:0070939 | |
| Domain | MADS_MEF2-like | 1.57e-09 | 4 | 119 | 4 | IPR033896 | |
| Domain | MADS_BOX_1 | 2.33e-08 | 6 | 119 | 4 | PS00350 | |
| Domain | MADS | 2.33e-08 | 6 | 119 | 4 | SM00432 | |
| Domain | SRF-TF | 2.33e-08 | 6 | 119 | 4 | PF00319 | |
| Domain | MADS_BOX_2 | 2.33e-08 | 6 | 119 | 4 | PS50066 | |
| Domain | TF_MADSbox | 5.40e-08 | 7 | 119 | 4 | IPR002100 | |
| Domain | HJURP_C | 1.00e-06 | 4 | 119 | 3 | IPR022102 | |
| Domain | HJURP_C | 1.00e-06 | 4 | 119 | 3 | PF12347 | |
| Domain | Znf_C2H2_jaz | 1.05e-05 | 22 | 119 | 4 | IPR022755 | |
| Domain | zf-C2H2_jaz | 1.05e-05 | 22 | 119 | 4 | PF12171 | |
| Domain | Clathrin_b-adaptin_app_Ig-like | 4.03e-05 | 2 | 119 | 2 | IPR013037 | |
| Domain | - | 4.03e-05 | 2 | 119 | 2 | 2.60.40.1150 | |
| Domain | Znf_C2H2-like | ZNF729 ZNF354A ZNF423 ZNF674 ZNF385B ZNF229 ZNF12 ZNF385D ZNF800 ZNF713 ZNF277 ZNF804B ZNF420 ZNF543 ZBTB11 ZFP82 | 4.53e-05 | 796 | 119 | 16 | IPR015880 |
| Domain | Znf_C2H2 | ZNF729 ZNF354A ZNF423 ZNF674 ZNF385B ZNF229 ZNF12 ZNF385D ZNF800 ZNF713 ZNF277 ZNF804B ZNF420 ZNF543 ZBTB11 ZFP82 | 5.18e-05 | 805 | 119 | 16 | IPR007087 |
| Domain | ZnF_C2H2 | ZNF729 ZNF354A ZNF423 ZNF674 ZNF385B ZNF229 ZNF12 ZNF385D ZNF800 ZNF713 ZNF277 ZNF804B ZNF420 ZNF543 ZBTB11 ZFP82 | 5.41e-05 | 808 | 119 | 16 | SM00355 |
| Domain | AP_complex_bsu_1_2_4 | 1.20e-04 | 3 | 119 | 2 | IPR016342 | |
| Domain | B2-adapt-app_C | 1.20e-04 | 3 | 119 | 2 | PF09066 | |
| Domain | zf-C2H2_6 | ZNF729 ZNF354A ZNF423 ZNF229 ZNF12 ZNF420 ZNF543 ZBTB11 ZFP82 | 1.83e-04 | 314 | 119 | 9 | PF13912 |
| Domain | Ubiquitin_3 | 2.40e-04 | 4 | 119 | 2 | PF14836 | |
| Domain | Ub_USP-typ | 2.40e-04 | 4 | 119 | 2 | IPR028135 | |
| Domain | B2-adapt-app_C | 2.40e-04 | 4 | 119 | 2 | SM01020 | |
| Domain | TF_AF4/FMR2 | 2.40e-04 | 4 | 119 | 2 | IPR007797 | |
| Domain | B-adaptin_app_sub_C | 2.40e-04 | 4 | 119 | 2 | IPR015151 | |
| Domain | AF-4 | 2.40e-04 | 4 | 119 | 2 | PF05110 | |
| Domain | AP_beta | 3.98e-04 | 5 | 119 | 2 | IPR026739 | |
| Domain | ZINC_FINGER_C2H2_2 | ZNF729 ZNF354A ZNF423 ZNF674 ZNF229 ZNF12 ZNF800 ZNF713 ZNF277 ZNF804B ZNF420 ZNF543 ZBTB11 ZFP82 | 4.17e-04 | 775 | 119 | 14 | PS50157 |
| Domain | ZINC_FINGER_C2H2_1 | ZNF729 ZNF354A ZNF423 ZNF674 ZNF229 ZNF12 ZNF800 ZNF713 ZNF277 ZNF804B ZNF420 ZNF543 ZBTB11 ZFP82 | 4.28e-04 | 777 | 119 | 14 | PS00028 |
| Domain | KRAB | ZNF729 ZNF354A ZNF674 ZNF229 ZNF12 ZNF713 ZNF420 ZNF543 ZFP82 | 4.80e-04 | 358 | 119 | 9 | PS50805 |
| Domain | KRAB | ZNF729 ZNF354A ZNF674 ZNF229 ZNF12 ZNF713 ZNF420 ZNF543 ZFP82 | 4.80e-04 | 358 | 119 | 9 | PF01352 |
| Domain | DUSP | 5.94e-04 | 6 | 119 | 2 | PF06337 | |
| Domain | DUSP | 5.94e-04 | 6 | 119 | 2 | SM00695 | |
| Domain | Beta2_adaptin/TBP_C_dom | 5.94e-04 | 6 | 119 | 2 | IPR012295 | |
| Domain | - | 5.94e-04 | 6 | 119 | 2 | 3.30.310.10 | |
| Domain | KRAB | ZNF729 ZNF354A ZNF674 ZNF229 ZNF12 ZNF713 ZNF420 ZNF543 ZFP82 | 5.97e-04 | 369 | 119 | 9 | SM00349 |
| Domain | KRAB | ZNF729 ZNF354A ZNF674 ZNF229 ZNF12 ZNF713 ZNF420 ZNF543 ZFP82 | 6.08e-04 | 370 | 119 | 9 | IPR001909 |
| Domain | DUSP | 8.28e-04 | 7 | 119 | 2 | PS51283 | |
| Domain | - | 8.28e-04 | 7 | 119 | 2 | 3.30.2230.10 | |
| Domain | Pept_C19_DUSP | 8.28e-04 | 7 | 119 | 2 | IPR006615 | |
| Domain | USP_CS | 8.33e-04 | 66 | 119 | 4 | IPR018200 | |
| Domain | USP_1 | 1.04e-03 | 70 | 119 | 4 | PS00972 | |
| Domain | UCH | 1.10e-03 | 71 | 119 | 4 | PF00443 | |
| Domain | USP_2 | 1.10e-03 | 71 | 119 | 4 | PS00973 | |
| Domain | Coatomer/calthrin_app_sub_C | 1.10e-03 | 8 | 119 | 2 | IPR009028 | |
| Domain | USP_3 | 1.15e-03 | 72 | 119 | 4 | PS50235 | |
| Domain | USP_dom | 1.15e-03 | 72 | 119 | 4 | IPR028889 | |
| Domain | Peptidase_C19_UCH | 1.15e-03 | 72 | 119 | 4 | IPR001394 | |
| Domain | Alpha_adaptinC2 | 1.41e-03 | 9 | 119 | 2 | PF02883 | |
| Domain | Clathrin_a/b/g-adaptin_app_Ig | 1.41e-03 | 9 | 119 | 2 | IPR008152 | |
| Domain | Alpha_adaptinC2 | 1.41e-03 | 9 | 119 | 2 | SM00809 | |
| Domain | zf-C2H2_11 | 1.41e-03 | 9 | 119 | 2 | PF16622 | |
| Domain | TPR | 1.42e-03 | 129 | 119 | 5 | SM00028 | |
| Domain | ATPase_P-typ_cyto_domN | 1.42e-03 | 35 | 119 | 3 | IPR023299 | |
| Domain | ATPase_P-typ_P_site | 1.54e-03 | 36 | 119 | 3 | IPR018303 | |
| Domain | P_typ_ATPase | 1.54e-03 | 36 | 119 | 3 | IPR001757 | |
| Domain | ATPASE_E1_E2 | 1.54e-03 | 36 | 119 | 3 | PS00154 | |
| Domain | zf-C2H2 | ZNF729 ZNF354A ZNF423 ZNF674 ZNF229 ZNF12 ZNF713 ZNF277 ZNF420 ZNF543 ZBTB11 ZFP82 | 1.57e-03 | 693 | 119 | 12 | PF00096 |
| Domain | Znf_C2H2/integrase_DNA-bd | ZNF729 ZNF354A ZNF423 ZNF674 ZNF229 ZNF12 ZNF800 ZNF713 ZNF420 ZNF543 ZBTB11 ZFP82 | 1.59e-03 | 694 | 119 | 12 | IPR013087 |
| Domain | TPR_repeat | 1.62e-03 | 133 | 119 | 5 | IPR019734 | |
| Domain | ATPase_P-typ_transduc_dom_A | 1.67e-03 | 37 | 119 | 3 | IPR008250 | |
| Domain | E1-E2_ATPase | 1.67e-03 | 37 | 119 | 3 | PF00122 | |
| Domain | - | 2.33e-03 | 449 | 119 | 9 | 3.30.40.10 | |
| Domain | Znf_FYVE_PHD | 2.51e-03 | 147 | 119 | 5 | IPR011011 | |
| Domain | Coatomer/clathrin_app_Ig-like | 2.55e-03 | 12 | 119 | 2 | IPR013041 | |
| Domain | Znf_C2H2_matrin | 2.55e-03 | 12 | 119 | 2 | IPR000690 | |
| Domain | Znf_RING/FYVE/PHD | 2.70e-03 | 459 | 119 | 9 | IPR013083 | |
| Domain | Znf_hrmn_rcpt | 3.14e-03 | 46 | 119 | 3 | IPR001628 | |
| Domain | NUCLEAR_REC_DBD_2 | 3.14e-03 | 46 | 119 | 3 | PS51030 | |
| Domain | NUCLEAR_REC_DBD_1 | 3.14e-03 | 46 | 119 | 3 | PS00031 | |
| Domain | ZnF_C4 | 3.14e-03 | 46 | 119 | 3 | SM00399 | |
| Domain | zf-C4 | 3.14e-03 | 46 | 119 | 3 | PF00105 | |
| Domain | Nuclear_hrmn_rcpt | 3.14e-03 | 46 | 119 | 3 | IPR001723 | |
| Domain | - | 3.33e-03 | 47 | 119 | 3 | 1.10.565.10 | |
| Domain | Dynein_heavy_chain_D4_dom | 3.48e-03 | 14 | 119 | 2 | IPR024317 | |
| Domain | Dynein_heavy_dom-2 | 3.48e-03 | 14 | 119 | 2 | IPR013602 | |
| Domain | DHC_N2 | 3.48e-03 | 14 | 119 | 2 | PF08393 | |
| Domain | P_typ_ATPase_c | 3.48e-03 | 14 | 119 | 2 | IPR032630 | |
| Domain | P-type_ATPase_N | 3.48e-03 | 14 | 119 | 2 | IPR032631 | |
| Domain | ATPase_dyneun-rel_AAA | 3.48e-03 | 14 | 119 | 2 | IPR011704 | |
| Domain | P-type_ATPase_IV | 3.48e-03 | 14 | 119 | 2 | IPR006539 | |
| Domain | AAA_8 | 3.48e-03 | 14 | 119 | 2 | PF12780 | |
| Domain | PhoLip_ATPase_C | 3.48e-03 | 14 | 119 | 2 | PF16212 | |
| Domain | PhoLip_ATPase_N | 3.48e-03 | 14 | 119 | 2 | PF16209 | |
| Domain | AAA_5 | 3.48e-03 | 14 | 119 | 2 | PF07728 | |
| Domain | Nucl_hrmn_rcpt_lig-bd | 3.54e-03 | 48 | 119 | 3 | IPR000536 | |
| Domain | HOLI | 3.54e-03 | 48 | 119 | 3 | SM00430 | |
| Domain | Hormone_recep | 3.54e-03 | 48 | 119 | 3 | PF00104 | |
| Domain | DHC_fam | 4.00e-03 | 15 | 119 | 2 | IPR026983 | |
| Domain | Clathrin/coatomer_adapt-like_N | 4.00e-03 | 15 | 119 | 2 | IPR002553 | |
| Domain | Dynein_heavy | 4.00e-03 | 15 | 119 | 2 | PF03028 | |
| Domain | Adaptin_N | 4.00e-03 | 15 | 119 | 2 | PF01602 | |
| Domain | Dynein_heavy_dom | 4.00e-03 | 15 | 119 | 2 | IPR004273 | |
| Domain | - | ZNF729 ZNF354A ZNF423 ZNF674 ZNF229 ZNF12 ZNF800 ZNF420 ZNF543 ZBTB11 ZFP82 | 4.08e-03 | 679 | 119 | 11 | 3.30.160.60 |
| Domain | TPR_REGION | 4.12e-03 | 165 | 119 | 5 | PS50293 | |
| Domain | TPR | 4.12e-03 | 165 | 119 | 5 | PS50005 | |
| Domain | TPR_8 | 4.69e-03 | 53 | 119 | 3 | PF13181 | |
| Domain | - | 5.75e-03 | 57 | 119 | 3 | 3.30.50.10 | |
| Domain | ZF_MATRIN | 5.76e-03 | 18 | 119 | 2 | PS50171 | |
| Domain | KAZAL_1 | 5.76e-03 | 18 | 119 | 2 | PS00282 | |
| Domain | BTB | 5.93e-03 | 180 | 119 | 5 | SM00225 | |
| Domain | Znf_NHR/GATA | 6.03e-03 | 58 | 119 | 3 | IPR013088 | |
| Pathway | WP_SRF_AND_MIRS_IN_SMOOTH_MUSCLE_DIFFERENTIATION_AND_PROLIFERATION | 5.06e-06 | 18 | 93 | 4 | M39393 | |
| Pathway | WP_ENERGY_METABOLISM | 1.53e-05 | 48 | 93 | 5 | M39590 | |
| Pathway | REACTOME_MYOGENESIS | 3.72e-05 | 29 | 93 | 4 | M853 | |
| Pubmed | 1.49e-10 | 4 | 123 | 4 | 22764880 | ||
| Pubmed | 1.49e-10 | 4 | 123 | 4 | 8575763 | ||
| Pubmed | 1.49e-10 | 4 | 123 | 4 | 10207130 | ||
| Pubmed | 1.49e-10 | 4 | 123 | 4 | 21531906 | ||
| Pubmed | Expression of mef2 genes in the mouse central nervous system suggests a role in neuronal maturation. | 1.49e-10 | 4 | 123 | 4 | 7643214 | |
| Pubmed | 1.49e-10 | 4 | 123 | 4 | 25416778 | ||
| Pubmed | The MEF2B homologue differentially expressed in mouse embryonal carcinoma cells. | 7.43e-10 | 5 | 123 | 4 | 7646512 | |
| Pubmed | 7.43e-10 | 5 | 123 | 4 | 8993831 | ||
| Pubmed | Galpha13 regulates MEF2-dependent gene transcription in endothelial cells: role in angiogenesis. | 7.43e-10 | 5 | 123 | 4 | 19093215 | |
| Pubmed | Calcineurin initiates skeletal muscle differentiation by activating MEF2 and MyoD. | 7.43e-10 | 5 | 123 | 4 | 12694204 | |
| Pubmed | 7.43e-10 | 5 | 123 | 4 | 10458488 | ||
| Pubmed | Regulatory role of MEF2D in serum induction of the c-jun promoter. | 7.43e-10 | 5 | 123 | 4 | 7760790 | |
| Pubmed | 7.43e-10 | 5 | 123 | 4 | 16504037 | ||
| Pubmed | The expression of MEF2 genes is implicated in CNS neuronal differentiation. | 2.22e-09 | 6 | 123 | 4 | 9013788 | |
| Pubmed | MEF2B Instructs Germinal Center Development and Acts as an Oncogene in B Cell Lymphomagenesis. | 1.03e-08 | 8 | 123 | 4 | 30205047 | |
| Pubmed | 3.08e-08 | 10 | 123 | 4 | 30276662 | ||
| Pubmed | An intragenic MEF2-dependent enhancer directs muscle-specific expression of microRNAs 1 and 133. | 4.32e-08 | 3 | 123 | 3 | 18093911 | |
| Pubmed | In vivo analysis of MEF2 transcription factors in synapse regulation and neuronal survival. | 4.32e-08 | 3 | 123 | 3 | 22496871 | |
| Pubmed | 4.32e-08 | 3 | 123 | 3 | 27989458 | ||
| Pubmed | 4.32e-08 | 3 | 123 | 3 | 15834131 | ||
| Pubmed | 4.32e-08 | 3 | 123 | 3 | 26286136 | ||
| Pubmed | 4.32e-08 | 3 | 123 | 3 | 33315889 | ||
| Pubmed | Control of mouse cardiac morphogenesis and myogenesis by transcription factor MEF2C. | 4.82e-08 | 11 | 123 | 4 | 9162005 | |
| Pubmed | KDM5B TRAF2 WASHC4 TRIO ZNF423 ASH1L RNF40 NR1D1 LRP1B TF RXRG USP8 RBM22 AP2B1 RCBTB1 ASPA ZBTB11 CABIN1 XRCC6 | 1.35e-07 | 1285 | 123 | 19 | 35914814 | |
| Pubmed | 1.45e-07 | 14 | 123 | 4 | 12130539 | ||
| Pubmed | Requirement of MEF2A, C, and D for skeletal muscle regeneration. | 1.72e-07 | 4 | 123 | 3 | 24591619 | |
| Pubmed | Apoptosis of T cells mediated by Ca2+-induced release of the transcription factor MEF2. | 1.72e-07 | 4 | 123 | 3 | 10531067 | |
| Pubmed | 1.72e-07 | 4 | 123 | 3 | 31420455 | ||
| Pubmed | 1.72e-07 | 4 | 123 | 3 | 8817457 | ||
| Pubmed | UIMC1 WASHC4 ZFYVE16 ASH1L SVEP1 PTPRC AP1B1 TRIM62 HTATSF1 PLCG2 CAMSAP1 ZBTB11 XRCC6 | 1.93e-07 | 591 | 123 | 13 | 15231748 | |
| Pubmed | MEF2C transcription factor controls chondrocyte hypertrophy and bone development. | 3.42e-07 | 17 | 123 | 4 | 17336904 | |
| Pubmed | Control of the SOST bone enhancer by PTH using MEF2 transcription factors. | 4.29e-07 | 5 | 123 | 3 | 17696759 | |
| Pubmed | 4.29e-07 | 5 | 123 | 3 | 15084602 | ||
| Pubmed | Interaction of myocyte enhancer factor 2 (MEF2) with a mitogen-activated protein kinase, ERK5/BMK1. | 4.29e-07 | 5 | 123 | 3 | 9753748 | |
| Pubmed | Regulation of the MEF2 family of transcription factors by p38. | 4.29e-07 | 5 | 123 | 3 | 9858528 | |
| Pubmed | 4.29e-07 | 5 | 123 | 3 | 20833138 | ||
| Pubmed | 4.29e-07 | 5 | 123 | 3 | 23511190 | ||
| Pubmed | 4.29e-07 | 5 | 123 | 3 | 8900141 | ||
| Pubmed | MEF2 transcription factors are key regulators of sprouting angiogenesis. | 4.29e-07 | 5 | 123 | 3 | 27898394 | |
| Pubmed | Calcium regulates transcriptional repression of myocyte enhancer factor 2 by histone deacetylase 4. | 8.57e-07 | 6 | 123 | 3 | 10825153 | |
| Pubmed | 8.57e-07 | 6 | 123 | 3 | 20399744 | ||
| Pubmed | 8.57e-07 | 6 | 123 | 3 | 10737771 | ||
| Pubmed | Mef2 gene expression marks the cardiac and skeletal muscle lineages during mouse embryogenesis. | 1.50e-06 | 7 | 123 | 3 | 8026334 | |
| Pubmed | 1.50e-06 | 7 | 123 | 3 | 12861002 | ||
| Pubmed | USP18 TRAF2 GALNT1 RNF40 LRP1B GALNT13 SULT1E1 AP1B1 AP2B1 KCNG1 ATP2C2 USP4 USP15 | 2.04e-06 | 730 | 123 | 13 | 34857952 | |
| Pubmed | 2.39e-06 | 8 | 123 | 3 | 16043483 | ||
| Pubmed | Histone deacetylase degradation and MEF2 activation promote the formation of slow-twitch myofibers. | 2.39e-06 | 8 | 123 | 3 | 17786239 | |
| Pubmed | KDM5B ZFYVE16 RNF40 CHEK1 BRMS1L BCR BRCA2 CAMSAP1 ZBTB11 CDC23 | 2.53e-06 | 418 | 123 | 10 | 34709266 | |
| Pubmed | TTC39B CISD2 RNF40 BCR ZNF12 USP8 CSF3 BRCA2 SYNE2 HTATSF1 ALB PLCG2 XRCC6 | 2.91e-06 | 754 | 123 | 13 | 35906200 | |
| Pubmed | 3.57e-06 | 9 | 123 | 3 | 9738004 | ||
| Pubmed | 4.96e-06 | 32 | 123 | 4 | 21768366 | ||
| Pubmed | 4.96e-06 | 32 | 123 | 4 | 20111592 | ||
| Pubmed | Mef2d is essential for the maturation and integrity of retinal photoreceptor and bipolar cells. | 4.96e-06 | 32 | 123 | 4 | 25757744 | |
| Pubmed | 7.33e-06 | 199 | 123 | 7 | 23382691 | ||
| Pubmed | 8.04e-06 | 36 | 123 | 4 | 22626734 | ||
| Pubmed | 9.28e-06 | 12 | 123 | 3 | 28641113 | ||
| Pubmed | Skeletal muscle specification by myogenin and Mef2D via the SWI/SNF ATPase Brg1. | 9.28e-06 | 12 | 123 | 3 | 16424906 | |
| Pubmed | 1.20e-05 | 13 | 123 | 3 | 21447557 | ||
| Pubmed | Myocyte enhancer factors 2A and 2C induce dilated cardiomyopathy in transgenic mice. | 1.24e-05 | 2 | 123 | 2 | 16469744 | |
| Pubmed | 1.24e-05 | 2 | 123 | 2 | 25336633 | ||
| Pubmed | 1.24e-05 | 2 | 123 | 2 | 9430690 | ||
| Pubmed | 1.24e-05 | 2 | 123 | 2 | 15299084 | ||
| Pubmed | 1.24e-05 | 2 | 123 | 2 | 12821652 | ||
| Pubmed | Revisiting the human polypeptide GalNAc-T1 and T13 paralogs. | 1.24e-05 | 2 | 123 | 2 | 27913570 | |
| Pubmed | Loss of myocyte enhancer factor 2 expression in osteoclasts leads to opposing skeletal phenotypes. | 1.24e-05 | 2 | 123 | 2 | 32512162 | |
| Pubmed | Regulation of myocyte enhancer factor-2 transcription factors by neurotoxins. | 1.24e-05 | 2 | 123 | 2 | 21741404 | |
| Pubmed | Molecular Pathway to Protection From Age-Dependent Photoreceptor Degeneration in Mef2 Deficiency. | 1.24e-05 | 2 | 123 | 2 | 28738418 | |
| Pubmed | 1.24e-05 | 2 | 123 | 2 | 17611778 | ||
| Pubmed | 1.24e-05 | 2 | 123 | 2 | 19023129 | ||
| Pubmed | 1.24e-05 | 2 | 123 | 2 | 33369070 | ||
| Pubmed | Analysis of albumin-associated peptides and proteins from ovarian cancer patients. | 1.24e-05 | 2 | 123 | 2 | 16099937 | |
| Pubmed | Lysine metabolism is a novel metabolic tumor suppressor pathway in breast cancer. | 1.24e-05 | 2 | 123 | 2 | 37393340 | |
| Pubmed | MEF2D and MEF2C pathways disruption in sporadic and familial ALS patients. | 1.24e-05 | 2 | 123 | 2 | 26921792 | |
| Pubmed | Adipocyte NR1D1 dictates adipose tissue expansion during obesity. | 1.24e-05 | 2 | 123 | 2 | 34350828 | |
| Pubmed | Nuclear receptor REVERBα is a state-dependent regulator of liver energy metabolism. | 1.24e-05 | 2 | 123 | 2 | 32989157 | |
| Pubmed | Bifunctional role of Rev-erbalpha in adipocyte differentiation. | 1.24e-05 | 2 | 123 | 2 | 18227153 | |
| Pubmed | 1.24e-05 | 2 | 123 | 2 | 8798771 | ||
| Pubmed | 1.24e-05 | 2 | 123 | 2 | 12079280 | ||
| Pubmed | MEF2 negatively regulates learning-induced structural plasticity and memory formation. | 1.24e-05 | 2 | 123 | 2 | 22885849 | |
| Pubmed | G-CSF induces E-selectin ligand expression on human myeloid cells. | 1.24e-05 | 2 | 123 | 2 | 16980970 | |
| Pubmed | 1.24e-05 | 2 | 123 | 2 | 20510503 | ||
| Pubmed | 1.24e-05 | 2 | 123 | 2 | 31722213 | ||
| Pubmed | 1.24e-05 | 2 | 123 | 2 | 30699340 | ||
| Pubmed | 1.24e-05 | 2 | 123 | 2 | 12615696 | ||
| Pubmed | Insulin downregulates C3 gene expression in human HepG2 cells through activation of PPARγ. | 1.24e-05 | 2 | 123 | 2 | 29550264 | |
| Pubmed | A Mef2 gene that generates a muscle-specific isoform via alternative mRNA splicing. | 1.53e-05 | 14 | 123 | 3 | 8114702 | |
| Pubmed | Deubiquitinating enzymes: a new class of biological regulators. | 1.90e-05 | 15 | 123 | 3 | 9827704 | |
| Pubmed | Influence of natriuretic peptide receptor-1 on survival and cardiac hypertrophy during development. | 1.90e-05 | 15 | 123 | 3 | 19782130 | |
| Pubmed | Multiplexed kinase interactome profiling quantifies cellular network activity and plasticity. | TRAF2 WASHC4 TRIO AFF3 CHEK1 BCR C4orf36 KSR1 PPP2R2A PPP6C AP1B1 AP2B1 CDC23 | 2.15e-05 | 910 | 123 | 13 | 36736316 |
| Pubmed | 2.83e-05 | 17 | 123 | 3 | 27779093 | ||
| Pubmed | 3.27e-05 | 51 | 123 | 4 | 20682687 | ||
| Pubmed | 3.39e-05 | 18 | 123 | 3 | 23211419 | ||
| Pubmed | 3.42e-05 | 451 | 123 | 9 | 36168627 | ||
| Pubmed | 3.71e-05 | 3 | 123 | 2 | 21105983 | ||
| Pubmed | Nuclear hormone receptor coregulators in action: diversity for shared tasks. | 3.71e-05 | 3 | 123 | 2 | 10707952 | |
| Pubmed | 3.71e-05 | 3 | 123 | 2 | 34620682 | ||
| Pubmed | 3.71e-05 | 3 | 123 | 2 | 28901289 | ||
| Pubmed | 3.71e-05 | 3 | 123 | 2 | 11792813 | ||
| Pubmed | 3.71e-05 | 3 | 123 | 2 | 23884886 | ||
| Pubmed | 3.71e-05 | 3 | 123 | 2 | 19861535 | ||
| Interaction | MEF2B interactions | 3.22e-09 | 11 | 121 | 5 | int:MEF2B | |
| Interaction | BORCS8-MEF2B interactions | 2.05e-08 | 15 | 121 | 5 | int:BORCS8-MEF2B | |
| Interaction | BRAP interactions | 1.81e-06 | 96 | 121 | 7 | int:BRAP | |
| Interaction | MEF2A interactions | 6.42e-06 | 76 | 121 | 6 | int:MEF2A | |
| Interaction | HDAC1 interactions | DCAF1 KDM5B ZFYVE16 ZNF423 RNF40 BRMS1L PPARG BCR MEF2A MEF2D PPP2R2A ZNF800 NCAPG BRCA2 SYNE2 CAMSAP1 ZBTB11 CABIN1 USP15 CDC23 | 9.44e-06 | 1108 | 121 | 20 | int:HDAC1 |
| Interaction | NOTCH1 interactions | USP18 RNF40 MEF2C STC1 USP8 PPP2R2A HTATSF1 USP15 XRCC6 CDC23 | 4.47e-05 | 345 | 121 | 10 | int:NOTCH1 |
| Cytoband | 16q12 | 1.06e-04 | 6 | 123 | 2 | 16q12 | |
| Cytoband | 17q11.2-q12 | 1.48e-04 | 7 | 123 | 2 | 17q11.2-q12 | |
| Cytoband | 5q14 | 3.16e-04 | 10 | 123 | 2 | 5q14 | |
| GeneFamily | Myocyte enhancer factor 2 proteins|MADS box family | 7.78e-10 | 4 | 97 | 4 | 649 | |
| GeneFamily | Myocyte enhancer factor 2 proteins|MADS box family | 3.88e-09 | 5 | 97 | 4 | 1086 | |
| GeneFamily | AF4/FMR2 family|Super elongation complex | 1.70e-04 | 4 | 97 | 2 | 1145 | |
| GeneFamily | Ubiquitin specific peptidases | 2.31e-04 | 56 | 97 | 4 | 366 | |
| GeneFamily | Zinc fingers C2H2-type|ZF class homeoboxes and pseudogenes | ZNF729 ZNF354A ZNF423 ZNF674 ZNF229 ZNF12 ZNF800 ZNF713 ZNF420 ZNF543 ZBTB11 ZFP82 | 4.54e-04 | 718 | 97 | 12 | 28 |
| GeneFamily | AF4/FMR2 family|Super elongation complex | 1.00e-03 | 9 | 97 | 2 | 1280 | |
| GeneFamily | Nuclear hormone receptors | 2.31e-03 | 49 | 97 | 3 | 71 | |
| GeneFamily | ATPase phospholipid transporting | 2.86e-03 | 15 | 97 | 2 | 1210 | |
| GeneFamily | Dyneins, axonemal | 3.68e-03 | 17 | 97 | 2 | 536 | |
| GeneFamily | Polypeptide N-acetylgalactosaminyltransferases | 5.08e-03 | 20 | 97 | 2 | 433 | |
| Coexpression | GSE21670_UNTREATED_VS_TGFB_IL6_TREATED_CD4_TCELL_UP | 3.88e-06 | 194 | 123 | 8 | M7467 | |
| Coexpression | GSE22886_NAIVE_CD4_TCELL_VS_NKCELL_DN | 4.51e-06 | 198 | 123 | 8 | M4424 | |
| Coexpression | GSE5542_UNTREATED_VS_IFNA_AND_IFNG_TREATED_EPITHELIAL_CELLS_24H_UP | 4.68e-06 | 199 | 123 | 8 | M6527 | |
| Coexpression | GAO_ESOPHAGUS_25W_C4_FGFR1HIGH_EPITHELIAL_CELLS | 6.48e-06 | 208 | 123 | 8 | M39139 | |
| Coexpression | GSE37534_UNTREATED_VS_GW1929_TREATED_CD4_TCELL_PPARG1_AND_FOXP3_TRASDUCED_UP | 4.42e-05 | 199 | 123 | 7 | M8978 | |
| Coexpression | GSE360_L_DONOVANI_VS_M_TUBERCULOSIS_DC_UP | 4.42e-05 | 199 | 123 | 7 | M5205 | |
| Coexpression | GSE360_L_DONOVANI_VS_B_MALAYI_LOW_DOSE_DC_DN | 4.56e-05 | 200 | 123 | 7 | M5204 | |
| Coexpression | GSE24210_RESTING_TREG_VS_TCONV_UP | 4.56e-05 | 200 | 123 | 7 | M7839 | |
| Coexpression | GSE20715_0H_VS_48H_OZONE_TLR4_KO_LUNG_UP | 4.56e-05 | 200 | 123 | 7 | M4379 | |
| Coexpression | HADDAD_B_LYMPHOCYTE_PROGENITOR | 6.99e-05 | 290 | 123 | 8 | M939 | |
| CoexpressionAtlas | B cells, proB.FrA.BM, CD19- IgM- CD43+ CD24intermediate CD45R+ AA4.1+ CD, Bone marrow, avg-2 | AFF3 CHEK1 BCR TF CLEC12A MEF2C GFRA1 NCAPG BRCA2 KCNG1 SYNE2 C3 POLQ XRCC6 | 3.81e-08 | 388 | 119 | 14 | GSM538352_500 |
| CoexpressionAtlas | B cells, proB.CLP.BM, AA4.1+ CD117+ IL7R+ CD45R- CD24- CD19- IgM-, Bone marrow, avg-1 | AFF3 CHEK1 TF CLEC12A MEF2C MEF2D GFRA1 NCAPG BRCA2 C3 XRCC6 | 3.23e-06 | 338 | 119 | 11 | GSM538347_500 |
| CoexpressionAtlas | DevelopingGonad_e14.5_ ovary_emap-6699_k-means-cluster#5_top-relative-expression-ranked_1000 | 7.71e-06 | 179 | 119 | 8 | gudmap_developingGonad_e14.5_ ovary_1000_k5 | |
| CoexpressionAtlas | DevelopingGonad_e18.5_epididymis_emap-13166_top-relative-expression-ranked_1000 | GGNBP2 WASHC4 TRIO AFF3 ASH1L ZNF385B ZNF229 MEF2A MEF2C ADCY8 SULT1E1 NCAPG SYNE2 HTATSF1 C3 ZNF420 | 1.00e-05 | 799 | 119 | 16 | gudmap_developingGonad_e18.5_epididymis_1000 |
| CoexpressionAtlas | B cells, proB.CLP.BM, CD19- IgM- CD43+ CD24- AA4.1+ CD45R- CD117+ IL7R+, Bone marrow, avg-1 | AFF3 CHEK1 TF CLEC12A MEF2C GFRA1 NCAPG BRCA2 KCNG1 C3 XRCC6 | 1.77e-05 | 405 | 119 | 11 | GSM538343_500 |
| CoexpressionAtlas | DevelopingGonad_e16.5_epididymis_emap-29702_top-relative-expression-ranked_1000 | GGNBP2 NAA15 WASHC4 TRIO AFF3 ASH1L CHEK1 ZNF229 MEF2A MEF2C SVEP1 NCAPG SYNE2 HTATSF1 ZNF420 | 3.60e-05 | 790 | 119 | 15 | gudmap_developingGonad_e16.5_epididymis_1000 |
| CoexpressionAtlas | B cells, proB.FrA.BM, AA4.1+ CD117+ IL7R+ CD45R+ CD24- CD19- IgM-, Bone marrow, avg-1 | 5.48e-05 | 304 | 119 | 9 | GSM538354_500 | |
| CoexpressionAtlas | DevelopingGonad_e16.5_ovary_emap-9563_top-relative-expression-ranked_500 | GGNBP2 ASH1L ZNF229 MEF2A ZNF800 NCAPG SYNE2 ASPA SHCBP1L FST | 6.57e-05 | 387 | 119 | 10 | gudmap_developingGonad_e16.5_ovary_500 |
| CoexpressionAtlas | DevelopingGonad_e16.5_ovary_emap-9563_k-means-cluster#1_top-relative-expression-ranked_500 | 6.63e-05 | 39 | 119 | 4 | gudmap_developingGonad_e16.5_ovary_500_k1 | |
| CoexpressionAtlas | B cells, proB.CLP.BM, CD19- IgM- CD43+ CD24intermediate CD45R- AA4.1+ CD, Bone marrow, avg-2 | 8.46e-05 | 399 | 119 | 10 | GSM538345_500 | |
| CoexpressionAtlas | B cells, preB.FrC.BM, CD19+ IgM- CD45R+ CD43+ HSA+, Bone marrow, avg-3 | 1.04e-04 | 409 | 119 | 10 | GSM399452_500 | |
| CoexpressionAtlas | DevelopingGonad_e14.5_ ovary_emap-6699_top-relative-expression-ranked_1000 | GGNBP2 NAA15 ASH1L IPP ZNF385B CHEK1 ZNF229 MEF2A ZNF800 NCAPG BRCA2 SYNE2 ASPA FST | 1.14e-04 | 776 | 119 | 14 | gudmap_developingGonad_e14.5_ ovary_1000 |
| CoexpressionAtlas | DevelopingGonad_e18.5_ovary_emap-12283_top-relative-expression-ranked_1000 | GGNBP2 NAA15 WASHC4 ASH1L ZNF385B CHEK1 ZNF229 MEF2A ZNF800 NCAPG SYNE2 ASPA SHCBP1L FST | 1.18e-04 | 778 | 119 | 14 | gudmap_developingGonad_e18.5_ovary_1000 |
| CoexpressionAtlas | B cells, proB.CLP.FL, CD19- IgM- CD43+ CD24intermediate CD45R- AA4.1+ CD, Fetal Liver, avg-1 | 1.24e-04 | 418 | 119 | 10 | GSM538350_500 | |
| CoexpressionAtlas | B cells, proB.CLP.FL, CD19- IgM- CD43+ CD24intermediate AA4.1+ CD45R- CD, Fetal Liver, avg-2 | 1.26e-04 | 419 | 119 | 10 | GSM538348_500 | |
| CoexpressionAtlas | B cells, proB.FrA.FL, CD19- IgM- CD43+ CD24intermediate CD45R+ AA4.1+ CD, Fetal Liver, avg-1 | 1.34e-04 | 422 | 119 | 10 | GSM538357_500 | |
| CoexpressionAtlas | B cells, proB.FrA.FL, CD19- IgM- CD43+ CD24intermediate AA4.1+ CD45R+ CD, Fetal Liver, avg-2 | 1.34e-04 | 422 | 119 | 10 | GSM538355_500 | |
| CoexpressionAtlas | DevelopingGonad_P2_epididymis_emap-30199_top-relative-expression-ranked_1000 | GGNBP2 NAA15 WASHC4 AFF3 ASH1L ZNF229 MEF2A MEF2C ADCY8 SULT1E1 ZNF800 NCAPG SYNE2 C3 | 1.51e-04 | 797 | 119 | 14 | gudmap_developingGonad_P2_epididymis_1000 |
| CoexpressionAtlas | DevelopingGonad_P2_epididymis_emap-30199_k-means-cluster#4_top-relative-expression-ranked_1000 | 1.53e-04 | 90 | 119 | 5 | gudmap_developingGonad_P2_epididymis_1000_k4 | |
| CoexpressionAtlas | DevelopingGonad_e16.5_ovary_emap-9563_k-means-cluster#3_top-relative-expression-ranked_1000 | 1.78e-04 | 93 | 119 | 5 | gudmap_developingGonad_e16.5_ovary_1000_k3 | |
| CoexpressionAtlas | DevelopingGonad_e18.5_epididymis_emap-13166_k-means-cluster#4_top-relative-expression-ranked_1000 | 2.17e-04 | 97 | 119 | 5 | gudmap_developingGonad_e18.5_epididymis_1000_k4 | |
| CoexpressionAtlas | dev gonad_e13.5_F_MeioticGermCell_Oct_top-relative-expression-ranked_500 | 3.23e-04 | 385 | 119 | 9 | gudmap_dev gonad_e13.5_F_MeioticGermCell_Oct_500 | |
| CoexpressionAtlas | alpha beta T cells, T.DPbl.Th, 4+ 8+ TCR-/lo FSChi, Thymus, avg-3 | 4.11e-04 | 398 | 119 | 9 | GSM399397_500 | |
| CoexpressionAtlas | dev gonad_e12.5_F_GermCellOvary_Oct_k-means-cluster#3_top-relative-expression-ranked_500 | 4.58e-04 | 114 | 119 | 5 | gudmap_dev gonad_e12.5_F_GermCellOvary_Oct_k3_500 | |
| CoexpressionAtlas | dev gonad_e12.5_F_GermCellOvary_Oct_top-relative-expression-ranked_500 | 4.75e-04 | 406 | 119 | 9 | gudmap_dev gonad_e12.5_F_GermCellOvary_Oct_500 | |
| ToppCell | LPS-IL1RA+antiTNF-Endothelial-Endothelial-Vein|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 3.52e-09 | 193 | 123 | 9 | 7261c1ce30c796b61c6ec58e64a051baa24732ff | |
| ToppCell | LPS-antiTNF-Endothelial-Endothelial-Vein|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 6.44e-08 | 192 | 123 | 8 | 81baf1c4063469bb0c03a8602b40e387ba7b0dfb | |
| ToppCell | PCW_07-8.5-Mesenchymal-Mesenchymal_myocytic-mes_proliferating_SM_(20)|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung | 6.70e-08 | 193 | 123 | 8 | 516ea2c12bdc7a5dc676159d627e36f6abe13ef0 | |
| ToppCell | Parenchyma_Control_(B.)-Endothelial-TX-Endothelial-1|Parenchyma_Control_(B.) / Sample group, Lineage and Cell type | 7.85e-08 | 197 | 123 | 8 | f969685dee212f33a6f09e54c0cd1fd24ffef546 | |
| ToppCell | Lung_Parenchyma-Control-Endothelial-Endothelial-Endothelial-1|Control / Location, Disease Group, Cell group, Cell class (2021.03.09) | 7.85e-08 | 197 | 123 | 8 | 1a137af40697137bb9d2b5caf2b1ffda55f04461 | |
| ToppCell | Lung_Parenchyma-Control-Endothelial-Endothelial-Endothelial-1-|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 7.85e-08 | 197 | 123 | 8 | 96d63a8d00583e2aa0a38412e2ae27e23f399493 | |
| ToppCell | 5'-Adult-LargeIntestine-Hematopoietic-B_cells-Cycling_B_cell|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 5.37e-07 | 173 | 123 | 7 | b7e0193fd4983cb38d1bee441f608f73ee8743b9 | |
| ToppCell | RSV-Healthy-0|RSV / Virus stimulation, Condition and Cluster | 7.01e-07 | 180 | 123 | 7 | 974044056e2f7e909cb11c6f6ca89e58bf95f7e5 | |
| ToppCell | RSV-Healthy-0|Healthy / Virus stimulation, Condition and Cluster | 7.01e-07 | 180 | 123 | 7 | 703a1d0f9536af94d56757eb01221878d7b7fe61 | |
| ToppCell | Control-Endothelial_cells-Pulmonary_venous_endothelial_cells|Control / group, cell type (main and fine annotations) | 7.84e-07 | 183 | 123 | 7 | 46be9f96755c7b65aeac061d95d15abeb6466034 | |
| ToppCell | PCW_10-12-Mesenchymal-Mesenchymal_myocytic-mes_proliferating_SM_(20)|PCW_10-12 / Celltypes from embryonic and fetal-stage human lung | 1.12e-06 | 193 | 123 | 7 | bbdfda6665941cfa1965418bb91ef9ff43b1326f | |
| ToppCell | nucseq-Endothelial-Endothelial_Vascular-Endothelial_large_blood_vessel-VEC|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2 | 1.12e-06 | 193 | 123 | 7 | 9ba688b35a9ead5d04691b3f3f15484f02dbbd0d | |
| ToppCell | IPF-Endothelial-VE_Venous|IPF / Disease state, Lineage and Cell class | 1.12e-06 | 193 | 123 | 7 | 29a655fa80feaabe846c90a28363b037e22d24ae | |
| ToppCell | PCW_13-14-Mesenchymal-Mesenchymal_myocytic-mes_proliferating_SM_(20)|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung | 1.16e-06 | 194 | 123 | 7 | 590a9d4f054e6a3685daf752c9354650fcc7d18a | |
| ToppCell | Fetal_brain-organoid_Tanaka_cellReport-GW09-Macroglial-Glia_progenitor_cell|GW09 / Sample Type, Dataset, Time_group, and Cell type. | 1.24e-06 | 196 | 123 | 7 | 7be50b9156394dea44d7b8b476d4dd516abfafae | |
| ToppCell | PCW_10-12-Mesenchymal-Mesenchymal_fibroblastic-mes_immature1_(0)|PCW_10-12 / Celltypes from embryonic and fetal-stage human lung | 1.28e-06 | 197 | 123 | 7 | 11a4c417f035e554431a8f03be13b5eefa3530c0 | |
| ToppCell | IPF-Endothelial-VE_Peribronchial|Endothelial / Disease state, Lineage and Cell class | 1.33e-06 | 198 | 123 | 7 | b8bd1ba268480f54451648e01631b615a3401144 | |
| ToppCell | PBMC-Mild-Lymphocyte-T/NK-Other_T|Mild / Location, Disease Group, Cell group, Cell class (2021.03.09) | 1.37e-06 | 199 | 123 | 7 | 101f78fe6dd1bf9e2e4dd5ad8a970312b3540927 | |
| ToppCell | PBMC-Mild-Lymphocyte-T/NK-Other_T|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 1.37e-06 | 199 | 123 | 7 | e0fcec796afe75e42467ca86355b9fc5aa9ae0a1 | |
| ToppCell | COVID-19_Severe-immature_Neutrophil|COVID-19_Severe / Disease condition and Cell class | 1.37e-06 | 199 | 123 | 7 | f82fa9d651e78f9ebbe6264e00a48c54b1786a69 | |
| ToppCell | COVID-19_Severe-immature_Neutrophil-|COVID-19_Severe / Disease condition and Cell class | 1.37e-06 | 199 | 123 | 7 | 42ea0c19c455bdb0ae89b428d09c333104c670dc | |
| ToppCell | Parenchymal-10x5prime-Immune_Myeloid-Macrophage_alveolar-Macro_alv_dividing|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations | 1.42e-06 | 200 | 123 | 7 | 0cf7208eab0dc58fbea35e256c5cb55cdd4a4928 | |
| ToppCell | LPS_IL1RA_TNF-Endothelial-Endothelial-Vein|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type | 1.42e-06 | 200 | 123 | 7 | 7eb366b2c5394af7c77650bde6261e7dac67154e | |
| ToppCell | mild|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class | 1.42e-06 | 200 | 123 | 7 | 12f1685ce8f218433068e090c9d839cd5a1910bf | |
| ToppCell | 343B-Myeloid-Macrophage-FABP4+_Macrophage_proliferating_2|343B / Donor, Lineage, Cell class and subclass (all cells) | 7.09e-06 | 167 | 123 | 6 | 7efa0081e79f22b219eac64ffcaedb2179cde299 | |
| ToppCell | 343B-Epithelial_cells-Epithelial-J_(AT1-AT2_progenitors)-|343B / Donor, Lineage, Cell class and subclass (all cells) | 7.59e-06 | 169 | 123 | 6 | a949f547b53126a208819bade74a1ac9b2a36ea7 | |
| ToppCell | 343B-Epithelial_cells-Epithelial-J_(AT1-AT2_progenitors)|343B / Donor, Lineage, Cell class and subclass (all cells) | 7.59e-06 | 169 | 123 | 6 | 195d5cd60d646ac6d40a3321b2f739917e7aef14 | |
| ToppCell | renal_cortex_nuclei-Adult_normal_reference-Immune-Myeloid-Macrophage_Dendritic-Cycling_Mononuclear_Phagocyte|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group | 7.59e-06 | 169 | 123 | 6 | 54b13ab02b4c187f4754045ecfcf409749e7ccc0 | |
| ToppCell | droplet-Liver-LIVER_NPC-30m-Lymphocytic-B_cell|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 8.12e-06 | 171 | 123 | 6 | 20ac3de9c164b409b70a30a8b6544ea491ef7c0e | |
| ToppCell | systemic_lupus_erythematosus-managed-Lymphocytic_B-plasmablast-male|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex | 9.27e-06 | 175 | 123 | 6 | 89bf89466191da14896ed8928027f5b911436c22 | |
| ToppCell | droplet-Marrow-nan-3m-Lymphocytic-NK_cell|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 9.27e-06 | 175 | 123 | 6 | cf53a15bfb37b6019e7052ffdf594a9ac040900e | |
| ToppCell | 5'-Parenchyma_lung-Immune_Myeloid-Myeloid_macrophage-alveolar_macrophage-Alveolar_macrophage_proliferating-Alveolar_macrophage_proliferating_L.1.0.7.2|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 1.12e-05 | 181 | 123 | 6 | 73b1b59810f60e3e39ca1d5073a5a0d4f5377e6e | |
| ToppCell | 10x5'-Liver-Lymphocytic_T_CD4/8-lo-Cycling_T|Liver / Manually curated celltypes from each tissue | 1.16e-05 | 182 | 123 | 6 | 81557cdc88777f3bd4e1dd18a760b08fc29122ef | |
| ToppCell | COVID-19-Heart-EC_3|COVID-19 / Disease (COVID-19 only), tissue and cell type | 1.19e-05 | 183 | 123 | 6 | ff95382cfed592190d0636d2b750328471f82e0d | |
| ToppCell | droplet-Marrow-nan-3m|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.23e-05 | 184 | 123 | 6 | 1154a5ad7b8512272b7476f949ddac350910bfb7 | |
| ToppCell | COPD-Endothelial-VE_Venous|COPD / Disease state, Lineage and Cell class | 1.23e-05 | 184 | 123 | 6 | 44d716e7ba46a1ed03f5992631289653f8fd7d5e | |
| ToppCell | 343B-Epithelial_cells-Epithelial-J_(AT1-AT2_progenitors)|Epithelial_cells / Donor, Lineage, Cell class and subclass (all cells) | 1.23e-05 | 184 | 123 | 6 | 6b2449ac65a2322aa0479fba0d89828f243aabbe | |
| ToppCell | 343B-Epithelial_cells-Epithelial-J_(AT1-AT2_progenitors)-|Epithelial_cells / Donor, Lineage, Cell class and subclass (all cells) | 1.23e-05 | 184 | 123 | 6 | e90622b82fa7f16a1faaf7a4724c958f2d83341d | |
| ToppCell | facs-Lung-24m-Mesenchymal-myofibroblast-pericyte_cell-pericyte|24m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype | 1.27e-05 | 185 | 123 | 6 | a6cd90f8f30c7bdf66958cf403e73c193aa32f5e | |
| ToppCell | facs-Lung-24m-Mesenchymal-myofibroblast-pericyte_cell|24m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype | 1.27e-05 | 185 | 123 | 6 | 5053f932e2adfcf4d6faaecff2999ac53d8d7aa5 | |
| ToppCell | droplet-Marrow-nan-3m-Myeloid|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.27e-05 | 185 | 123 | 6 | 7adfa929930cfa795cbfbd9f1a0b439e08aa765d | |
| ToppCell | COVID-19-Endothelial_cells-Systemic_venous_endothelial_cells|COVID-19 / group, cell type (main and fine annotations) | 1.27e-05 | 185 | 123 | 6 | f5e14181f45c37d13ee9e017a4c8bc248c353676 | |
| ToppCell | 367C-Endothelial_cells-Endothelial-D|367C / Donor, Lineage, Cell class and subclass (all cells) | 1.35e-05 | 187 | 123 | 6 | 1342bc614bc4045263c2eb0a535a1dd6c64e7abe | |
| ToppCell | 367C-Endothelial_cells-Endothelial-D-|367C / Donor, Lineage, Cell class and subclass (all cells) | 1.35e-05 | 187 | 123 | 6 | 7aa206262b14b9f2aaa99e59da38b96c3594d2c9 | |
| ToppCell | renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Epithelial-Collecting_tubule_epithelial_cell-kidney_connecting_tubule_epithelial_cell_cycling|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group | 1.35e-05 | 187 | 123 | 6 | 057569c9437219ecc396aa6e673b1178a2273837 | |
| ToppCell | PCW_07-8.5-Mesenchymal-Mesenchymal_myocytic-mes_pericyte_(14)|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung | 1.48e-05 | 190 | 123 | 6 | 10125091ad648163777b02e9f0d5e8d7f17d44a5 | |
| ToppCell | PCW_05-06-Mesenchymal-Mesenchymal_myocytic-mes_proliferating_SM_(20)|PCW_05-06 / Celltypes from embryonic and fetal-stage human lung | 1.48e-05 | 190 | 123 | 6 | e83fa8b711aa79a1767818474f1c193b674b1c31 | |
| ToppCell | COVID-19-kidney-Proliferating_T_cell|COVID-19 / Disease (COVID-19 only), tissue and cell type | 1.52e-05 | 191 | 123 | 6 | bae388e0e9447d576e68465d73d8313ef6925ffa | |
| ToppCell | COVID-19-kidney-AQP1+PLVAP+EC|COVID-19 / Disease (COVID-19 only), tissue and cell type | 1.57e-05 | 192 | 123 | 6 | 27ff3621e177e7932dd44dd6baa81551ea75a874 | |
| ToppCell | 3'-Adult-LargeIntestine-Mesenchymal-fibroblastic-mLN_Stroma_(FMO2+)|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 1.57e-05 | 192 | 123 | 6 | 11867f30f0b420c18cb0b34d3990237aa737a0e8 | |
| ToppCell | renal_papilla_nuclei-Hypertensive_with+without-CKD-Endothelial-blood_vessel_endothelial_cell_of_kidney-arteriolar_vasa-recta_endothelial-Ascending_Vasa_Recta_Endothelial_Cell|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 1.62e-05 | 193 | 123 | 6 | 1f978e102a029a6beb10913052cd0a20c7253e8e | |
| ToppCell | IPF-Endothelial-VE_Venous|World / Disease state, Lineage and Cell class | 1.62e-05 | 193 | 123 | 6 | ef66a46e7ab44fcc4005a23416e6da478a4cce37 | |
| ToppCell | kidney_cells-Renal_AKI_(acute_kidney_injury)-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell_cycling-Cycling_Proximal_Tubule_Epithelial_Cell_S-high|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group | 1.66e-05 | 194 | 123 | 6 | 4c1d13d8cb6fb424655c67755ee6dbaf59d6b418 | |
| ToppCell | (7)_Epithelial_cells-(7)_Epithelial-J_(AT1-AT2_progenitors)|(7)_Epithelial_cells / Lung cell shreds - cell class (v4) and cell subclass (v4) | 1.66e-05 | 194 | 123 | 6 | 4d6ae2b25db11a4ae6dadee83be5c8c05b1225c3 | |
| ToppCell | 3'-Adult-Appendix-Endothelial-blood_vessel_EC-Mature_venous_EC|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 1.71e-05 | 195 | 123 | 6 | 6a0460d949ccda7c9fe76870d3ee6c2f60677d61 | |
| ToppCell | PCW_10-12-Mesenchymal-Mesenchymal_cycling-mes_proliferating1_(3)|PCW_10-12 / Celltypes from embryonic and fetal-stage human lung | 1.71e-05 | 195 | 123 | 6 | cec7df321f372d05c94f97d6bb18891a5cc3dec3 | |
| ToppCell | Bronchial-NucSeq-Endothelial-Endothelia_vascular-VE_systemic_venous|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 1.71e-05 | 195 | 123 | 6 | fde8e7b38b3631109b95ef111c5f6e3f9878cfbd | |
| ToppCell | (3)_Chondrocytes-(30)_Chondro|(3)_Chondrocytes / Cell class and subclass of bone marrow stroma cells in homeostatis | 1.71e-05 | 195 | 123 | 6 | f5597d3ed37770c6fa2b339f98a80ac7ecd4f9ff | |
| ToppCell | Smart-start-Cell-Wel_seq-Non-neoplastic-Myeloid-TAM-MG-TAM-MG_pro-infl_I|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 1.71e-05 | 195 | 123 | 6 | b6bf75669f267ecdc96818c7022db852e37a9fe1 | |
| ToppCell | PCW_07-8.5-Mesenchymal-Mesenchymal_cycling-mes_proliferating1_(3)|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung | 1.71e-05 | 195 | 123 | 6 | b65463a804fed2d9a3be9e528ca8b9c98469bc86 | |
| ToppCell | IPF-Endothelial-VE_Peribronchial|IPF / Disease state, Lineage and Cell class | 1.71e-05 | 195 | 123 | 6 | 2c3ad3cb79f11119ac69c413a938d21199145040 | |
| ToppCell | 5'-Parenchyma_lung-Endothelial-Blood_vessel_EC-vein_endothelial_cell-EC_venous_systemic-EC_venous_systemic_L.2.2.0.1|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 1.76e-05 | 196 | 123 | 6 | 5609b2d93172a488b35d854298a3a4e504e17e28 | |
| ToppCell | PCW_13-14-Mesenchymal-Mesenchymal_cycling-mes_proliferating1_(3)|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung | 1.76e-05 | 196 | 123 | 6 | df366d76ea55f49e349d622effa57c1535df8400 | |
| ToppCell | Smart-start-Cell-Wel_seq-Non-neoplastic-Myeloid-TAM-MG-TAM-MG_aging_sig-G|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 1.76e-05 | 196 | 123 | 6 | e54c08f88779f9fd453a4f5b85aed1f460d8a1e1 | |
| ToppCell | Parenchymal-NucSeq-Immune_Lymphocytic-B-B_cell|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 1.81e-05 | 197 | 123 | 6 | ccabb976b5d4800e87e550640454a893fdb3b1b6 | |
| ToppCell | PCW_10-12-Mesenchymal-Mesenchymal_cycling-mes_proliferating3_(7)|PCW_10-12 / Celltypes from embryonic and fetal-stage human lung | 1.81e-05 | 197 | 123 | 6 | 84ed777cdba569200a3ef1654d8a12f17fcfb7f1 | |
| ToppCell | severe-unassigned|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class | 1.81e-05 | 197 | 123 | 6 | 70704b149b2820b8601d2495b7cd9cbe91eda262 | |
| ToppCell | PCW_13-14-Mesenchymal-Mesenchymal_fibroblastic-mes_immature1_(0)|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung | 1.81e-05 | 197 | 123 | 6 | 0034bae02ee7fcfea520d453ca3c842ab6963b12 | |
| ToppCell | Control_saline-Epithelial_airway|Control_saline / Treatment groups by lineage, cell group, cell type | 1.87e-05 | 198 | 123 | 6 | e6863238e022ecfb6a8e3f4b7661b376e92c5d8f | |
| ToppCell | kidney_cells-Renal_AKI_(acute_kidney_injury)-Immune-Lymphocytic_T/NK-Cycling_Natural_Killer_Cell_/_Natural_Killer_T_Cell|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group | 1.87e-05 | 198 | 123 | 6 | d484ac79d6cd29f1d9c192d126c2099f737d5320 | |
| ToppCell | (0)_NK_cells-(0)_NK_Dividing|(0)_NK_cells / Lung cell shreds - cell class (v4) and cell subclass (v4) | 1.87e-05 | 198 | 123 | 6 | d9cdbc7d420472cb1ffb36ad9c8e53a61b7dbdeb | |
| ToppCell | Control_saline-Epithelial_airway-airway_epithelial|Control_saline / Treatment groups by lineage, cell group, cell type | 1.87e-05 | 198 | 123 | 6 | e7aa42e5fbd42c68f50cda4a8f3aa464c862c007 | |
| ToppCell | kidney_cells-Renal_AKI_(acute_kidney_injury)-Immune-Lymphocytic_T/NK-Cycling_Natural_Killer_Cell_/_Natural_Killer_T_Cell-|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group | 1.87e-05 | 198 | 123 | 6 | ac0be1666456cfa8d68588b187d65008e6d5c0e2 | |
| ToppCell | (0)_NK_dividing|World / Spleen cell shreds - cell class (v1) and cell subclass (v1) | 1.87e-05 | 198 | 123 | 6 | c5336d9b802393d6fd6f8446ea4bb6befeb97bfd | |
| ToppCell | T_cells-GZMK+GZMB+_T_cells|T_cells / Immune cells in Rheumatoid Arthritis Joint Synovial Tissues | 1.87e-05 | 198 | 123 | 6 | 085ba270f9defbf5ef45108c6d870e1d7c428479 | |
| ToppCell | Tracheal-10x3prime_v2-Endothelial-Endothelia_vascular-VE_systemic_venous|10x3prime_v2 / Cell types per location group and 10X technology with lineage, and cell group designations | 1.92e-05 | 199 | 123 | 6 | d359f3e1595ba8d8a3dc9eb2e8f2b61f3247c7a1 | |
| ToppCell | PBMC-Severe-Lymphocyte-T/NK-Other_T|Severe / Location, Disease Group, Cell group, Cell class (2021.03.09) | 1.92e-05 | 199 | 123 | 6 | 305a9ade5bbe8e981e7c641c9a5e0c9f8ef60470 | |
| ToppCell | Brain_organoid-organoid_Paulsen_bioRxiv-6_mon-Proliferating-Cycling_Progenitors|6_mon / Sample Type, Dataset, Time_group, and Cell type. | 1.92e-05 | 199 | 123 | 6 | a99516a5760f49a69b0fe45a9b2316e393252966 | |
| ToppCell | PBMC-Severe-Lymphocyte-T/NK-Other_T|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 1.92e-05 | 199 | 123 | 6 | fba48342066aab41a8bcb20db40a6df0158e1cbe | |
| ToppCell | Bronchial-NucSeq-Epithelial-Epi_alveolar-Dividing_AT2|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 1.92e-05 | 199 | 123 | 6 | 1d5a3366474c17e3df0ba5cf11b586655529e9bd | |
| ToppCell | Parenchymal-10x3prime_v2-Endothelial-Endothelia_vascular-VE_systemic_venous|10x3prime_v2 / Cell types per location group and 10X technology with lineage, and cell group designations | 1.92e-05 | 199 | 123 | 6 | d62a2cb81b01ae59969e0b2bbe99c1c9cc96fdaa | |
| ToppCell | Control_saline-Endothelial-Endothelial-FOXM1|Control_saline / Treatment groups by lineage, cell group, cell type | 1.97e-05 | 200 | 123 | 6 | 9bbc7b5561151f6ff65f40b3226271def732e5d9 | |
| ToppCell | Parenchymal-10x5prime-Endothelial-Endothelia_vascular-VE_pulmonary_venous|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations | 1.97e-05 | 200 | 123 | 6 | cb00760ae75c30b1cb8526534aabd4ffc7c21000 | |
| ToppCell | mLN-T_cell-cycling_gd_T|mLN / Region, Cell class and subclass | 1.97e-05 | 200 | 123 | 6 | 4efeef51f885ee8f6dd3911a536cc49e3c14da98 | |
| ToppCell | mLN-(1)_T_cell-(18)_cycling_gd_T|mLN / shred on region, Cell_type, and subtype | 1.97e-05 | 200 | 123 | 6 | e8a0a88a8344e80783931115bbe6cd5b62a4c1f7 | |
| ToppCell | 3'-Parenchyma_lung-Endothelial-Blood_vessel_EC-vein_endothelial_cell-EC_venous_systemic-EC_venous_systemic_L.2.2.0.1|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 1.97e-05 | 200 | 123 | 6 | 310c75e13be9194312a8b686804edcf13d44caf5 | |
| ToppCell | (18)_cycling_gd_T|World / shred on Cell_type and subtype | 2.15e-05 | 203 | 123 | 6 | 7d58929058c4769226a29febee1fd8ba64bc9f1a | |
| ToppCell | primary_visual_cortex-Neuronal-glutamatergic_neuron-L5_PT-L5_PT_VISp_C1ql2_Ptgfr|primary_visual_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype | 2.74e-05 | 127 | 123 | 5 | fb58f4b4d3722f4b9a2e4946c0244c5b70dd883b | |
| ToppCell | primary_visual_cortex-Neuronal-glutamatergic_neuron-L6_IT-L6_IT_VISp_Col18a1|primary_visual_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype | 5.69e-05 | 148 | 123 | 5 | fc80c02b51cf55a04ce550838ee2f41d8f656f41 | |
| ToppCell | PND01-03-samps-Myeloid-Macrophage-macrophage-B|PND01-03-samps / Age Group, Lineage, Cell class and subclass | 6.46e-05 | 152 | 123 | 5 | 5ce8920aedd39a4daf7082153b5e213707c14227 | |
| ToppCell | E16.5-samps-Myeloid-Fetal_macrophage-Proliferative_Myeloid|E16.5-samps / Age Group, Lineage, Cell class and subclass | 6.46e-05 | 152 | 123 | 5 | e427758a6e39052616a0d8ecec0c1299e81d1d3c | |
| ToppCell | PBMC-Mild-Lymphocyte-B-B_cell-B_naive-B_naive-5|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 6.87e-05 | 154 | 123 | 5 | 020697ae8463b18f9b4270c404f52ce4c0e90135 | |
| ToppCell | frontal_cortex-Neuronal-glutamatergic_neuron-L5_PT-L5_PT_ALM_Npsr1|frontal_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype | 7.52e-05 | 81 | 123 | 4 | 5d9b08bc1ae6ecb894c88c9784fdc4203682d087 | |
| ToppCell | TCGA-Bladder-Solid_Tissue_Normal-Urothelial_normal_tissue-Urothelial_normal_tissue|TCGA-Bladder / Sample_Type by Project: Shred V9 | 8.23e-05 | 160 | 123 | 5 | 8a41e2c96e0e170ac35daf6c403bf961b8d7c30b | |
| ToppCell | TCGA-Bladder-Solid_Tissue_Normal|TCGA-Bladder / Sample_Type by Project: Shred V9 | 8.23e-05 | 160 | 123 | 5 | d6678996e12eaf2b735f1dfae32418cb2fabf268 | |
| ToppCell | TCGA-Bladder-Solid_Tissue_Normal-Urothelial_normal_tissue|TCGA-Bladder / Sample_Type by Project: Shred V9 | 8.23e-05 | 160 | 123 | 5 | c8dc575562b463fd30832d322c28006f18f7ab9c | |
| ToppCell | E18.5-samps-Myeloid-Macrophage-macrophage_-_intermediate_-_unactivated|E18.5-samps / Age Group, Lineage, Cell class and subclass | 8.73e-05 | 162 | 123 | 5 | 60d3fe1f5cec4285b8774ff078ebcc6bfaec26ed | |
| ToppCell | E18.5-samps-Myeloid|E18.5-samps / Age Group, Lineage, Cell class and subclass | 8.73e-05 | 162 | 123 | 5 | 18e4a807e25f754a69e9eaaddfde40f8de9b8512 | |
| ToppCell | E18.5-samps-Myeloid-Macrophage|E18.5-samps / Age Group, Lineage, Cell class and subclass | 8.73e-05 | 162 | 123 | 5 | 0970e4eda60e3f015335e2726e6d565fb2f43372 | |
| ToppCell | 5'-Adult-Appendix-Epithelial-Tuft-related|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 8.73e-05 | 162 | 123 | 5 | ded08da888d8c481f0f96d1e0bfd03d617966910 | |
| Drug | Epiandrosterone [481-29-8]; Up 200; 13.8uM; MCF7; HT_HG-U133A | 1.05e-06 | 199 | 119 | 9 | 3306_UP | |
| Disease | intellectual disability (implicated_via_orthology) | 5.23e-07 | 75 | 116 | 6 | DOID:1059 (implicated_via_orthology) | |
| Disease | autism spectrum disorder (implicated_via_orthology) | 2.44e-06 | 152 | 116 | 7 | DOID:0060041 (implicated_via_orthology) | |
| Disease | Drug toxicity | 2.07e-05 | 84 | 116 | 5 | C0013221 | |
| Disease | Adverse reaction to drug | 2.07e-05 | 84 | 116 | 5 | C0041755 | |
| Disease | serum IgG glycosylation measurement | MEF2B ZNF423 LRP1B ADCY8 GFRA1 ZNF385D ZNF804B PLCG2 FST USP15 | 4.28e-05 | 523 | 116 | 10 | EFO_0005193 |
| Disease | Echinococcosis | 4.58e-05 | 3 | 116 | 2 | C0013502 | |
| Disease | Cystic Echinocccosis | 4.58e-05 | 3 | 116 | 2 | C4553297 | |
| Disease | Inappropriate ACTH Secretion Syndrome | 4.58e-05 | 3 | 116 | 2 | C0751220 | |
| Disease | Liver Failure, Acute | 1.13e-04 | 24 | 116 | 3 | C0162557 | |
| Disease | COVID-19 (is_marker_for) | 1.13e-04 | 63 | 116 | 4 | DOID:0080600 (is_marker_for) | |
| Disease | leiomyosarcoma | 1.52e-04 | 5 | 116 | 2 | C0023269 | |
| Disease | Pituitary-dependent Cushing's disease | 1.52e-04 | 5 | 116 | 2 | C0221406 | |
| Disease | Leiomyosarcoma, Epithelioid | 1.52e-04 | 5 | 116 | 2 | C0205815 | |
| Disease | Leiomyosarcoma, Myxoid | 1.52e-04 | 5 | 116 | 2 | C0205816 | |
| Disease | attention deficit hyperactivity disorder (implicated_via_orthology) | 1.81e-04 | 28 | 116 | 3 | DOID:1094 (implicated_via_orthology) | |
| Disease | Paratuberculosis | 2.27e-04 | 6 | 116 | 2 | C0030524 | |
| Disease | Idiopathic Membranous Glomerulonephritis | 2.27e-04 | 6 | 116 | 2 | C0086445 | |
| Disease | Heymann Nephritis | 2.27e-04 | 6 | 116 | 2 | C1704378 | |
| Disease | Membranous glomerulonephritis | 2.27e-04 | 6 | 116 | 2 | C0017665 | |
| Disease | Malignant neoplasm of liver | 2.51e-04 | 142 | 116 | 5 | C0345904 | |
| Disease | Liver neoplasms | 2.51e-04 | 142 | 116 | 5 | C0023903 | |
| Disease | serum iron measurement | 3.76e-04 | 86 | 116 | 4 | EFO_0006332 | |
| Disease | coenzyme Q10 measurement | 3.85e-04 | 36 | 116 | 3 | EFO_0007836 | |
| Disease | cognitive disorder (is_implicated_in) | 5.42e-04 | 9 | 116 | 2 | DOID:1561 (is_implicated_in) | |
| Disease | brain ischemia (is_implicated_in) | 6.75e-04 | 10 | 116 | 2 | DOID:2316 (is_implicated_in) | |
| Disease | Acute kidney injury | 6.90e-04 | 101 | 116 | 4 | C2609414 | |
| Disease | Acute Kidney Insufficiency | 6.90e-04 | 101 | 116 | 4 | C1565662 | |
| Disease | Kidney Failure, Acute | 6.90e-04 | 101 | 116 | 4 | C0022660 | |
| Disease | Hemolytic-Uremic Syndrome | 8.23e-04 | 11 | 116 | 2 | C0019061 | |
| Disease | reticulocyte measurement | AFF3 ASH1L PPARG ADCY8 ZNF800 PTPRC AP1B1 AP2B1 SYNE2 USP4 PLCG2 BAIAP3 | 9.14e-04 | 1053 | 116 | 12 | EFO_0010700 |
| Disease | middle cerebral artery infarction (is_implicated_in) | 9.86e-04 | 12 | 116 | 2 | DOID:3525 (is_implicated_in) | |
| Disease | disks large homolog 3 measurement | 9.86e-04 | 12 | 116 | 2 | EFO_0802472 | |
| Disease | mammographic density measurement | 1.01e-03 | 50 | 116 | 3 | EFO_0005941 | |
| Disease | Uveal Melanoma | 1.20e-03 | 53 | 116 | 3 | EFO_1000616 | |
| Disease | age at menopause | 1.27e-03 | 302 | 116 | 6 | EFO_0004704 | |
| Disease | Hepatitis | 1.56e-03 | 15 | 116 | 2 | C0019158 | |
| Disease | Insulin Resistance | 1.72e-03 | 60 | 116 | 3 | C0021655 | |
| Disease | Insulin Sensitivity | 1.72e-03 | 60 | 116 | 3 | C0920563 | |
| Disease | Diabetic Angiopathies | 1.77e-03 | 16 | 116 | 2 | C0011875 | |
| Disease | Urticaria | 1.77e-03 | 16 | 116 | 2 | C0042109 | |
| Disease | Microangiopathy, Diabetic | 1.77e-03 | 16 | 116 | 2 | C0025945 | |
| Disease | cutaneous melanoma, hair color | 1.89e-03 | 62 | 116 | 3 | EFO_0000389, EFO_0003924 | |
| Disease | Intellectual Disability | 1.98e-03 | 447 | 116 | 7 | C3714756 | |
| Disease | response to radiation, Urinary retention | 2.00e-03 | 17 | 116 | 2 | GO_0009314, HP_0000016 | |
| Disease | erythritol measurement | 2.00e-03 | 17 | 116 | 2 | EFO_0021171 | |
| Disease | total blood protein measurement | 2.03e-03 | 449 | 116 | 7 | EFO_0004536 | |
| Disease | monocyte count | SELE GALNT1 AFF2 ASH1L DEFB135 MEF2C MEF2D KSR1 PTPRC CSF3 RCBTB1 C3 CABIN1 | 2.08e-03 | 1320 | 116 | 13 | EFO_0005091 |
| Disease | noggin measurement | 2.25e-03 | 18 | 116 | 2 | EFO_0021995 | |
| Disease | C-C motif chemokine 3 measurement | 2.25e-03 | 18 | 116 | 2 | EFO_0008051 | |
| Disease | monocyte percentage of leukocytes | 2.42e-03 | 731 | 116 | 9 | EFO_0007989 | |
| Disease | age at menarche | 2.44e-03 | 594 | 116 | 8 | EFO_0004703 | |
| Disease | cortical surface area change measurement, age at assessment | 2.51e-03 | 19 | 116 | 2 | EFO_0008007, EFO_0021503 | |
| Disease | Cannabis use, age at onset | 2.51e-03 | 19 | 116 | 2 | EFO_0004847, EFO_0007585 | |
| Disease | reticulocyte count | ASH1L PPARG ADCY8 ZNF800 PTPRC AP1B1 AP2B1 SYNE2 USP4 PLCG2 BAIAP3 | 2.78e-03 | 1045 | 116 | 11 | EFO_0007986 |
| Disease | platelet component distribution width | 3.00e-03 | 755 | 116 | 9 | EFO_0007984 | |
| Disease | melanoma | 3.03e-03 | 248 | 116 | 5 | C0025202 | |
| Disease | total iron binding capacity | 3.63e-03 | 78 | 116 | 3 | EFO_0006334 | |
| Disease | Immunologic Deficiency Syndromes | 3.67e-03 | 23 | 116 | 2 | C0021051 | |
| Disease | sex interaction measurement, body mass index, age at assessment | 3.67e-03 | 23 | 116 | 2 | EFO_0004340, EFO_0008007, EFO_0008343 | |
| Disease | Autistic Disorder | 3.77e-03 | 261 | 116 | 5 | C0004352 | |
| Disease | age of onset of asthma | 3.77e-03 | 79 | 116 | 3 | OBA_2001001 |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| EEEKAKRLLYCSLCK | 196 | Q9H6B1 | |
| KRLLYCSLCKVAVNS | 201 | Q9H6B1 | |
| EDKQLAALCYRCLAL | 1056 | P51826 | |
| AEDYKCLPLILRKTC | 761 | P40145 | |
| DLGVCLEYECKRKQL | 156 | A8K979 | |
| QEEIKEYKARLTCPC | 936 | O75150 | |
| KDDDVIRCICGLYKD | 2581 | Q9NR48 | |
| ECYEKLNQLVEAKKC | 441 | Q9UJX2 | |
| TLILNYCQCLLKKEE | 231 | Q9NZN9 | |
| LRLAKTYETTLEKCC | 371 | P02768 | |
| DKITEYLCEPLRKCL | 116 | P63010 | |
| ADKSYQCLKETCEKL | 386 | O14757 | |
| SKLCSLYENDCIFDK | 331 | P63151 | |
| KCSTRECIEQFYLDK | 986 | O94812 | |
| LEGSQTLRILCYEKC | 966 | P11274 | |
| GDKKLAVLCYRCLSL | 1151 | P51816 | |
| CVIKDNRLLCYKSSK | 196 | Q8N4X5 | |
| SIEDQKCYCERLKVK | 431 | A6NC57 | |
| CTLLKERQCQYEKEK | 836 | A6NC57 | |
| KKVFLDCCNYITELR | 721 | P01024 | |
| DKITEYLCEPLRKCL | 116 | Q10567 | |
| VEKIRLCKCHYIEDD | 126 | Q99766 | |
| ELYCRVCSLILKGDQ | 86 | Q5T5Y3 | |
| ILSELLKLCEKYCCS | 921 | O75185 | |
| LRTLCLCYKEIEEKE | 651 | O43520 | |
| LCIAKRVLSKEEYAC | 811 | O60312 | |
| VEEEDRCKLYCKAEN | 676 | Q8TE60 | |
| LATSYCENRLKKLCQ | 446 | Q8NDN9 | |
| KLKNVCQTCLLDLEY | 76 | Q9NW64 | |
| LASKKLCADDECVYT | 26 | Q9NRC9 | |
| ALQTLLKEYCEVCKS | 251 | Q9Y573 | |
| RDDVTYNIICKKCRA | 351 | P54762 | |
| KRNIFDLCTDTKDCY | 1351 | Q9Y4B6 | |
| CCLEEYRDRKKENAE | 131 | Q9NSA2 | |
| CKDKSDEKLLYCENR | 2536 | Q9NZR2 | |
| KILCKDPALELSCYR | 6 | A6PVI3 | |
| CTDCKNKVLRAYNIL | 216 | Q9H3C7 | |
| DCNCQKLYLDLDVIR | 491 | Q9H8L6 | |
| QDIIKDCYGITKCDR | 481 | Q8N6Q8 | |
| LEAKLVRYICKQRQC | 76 | Q8IVT5 | |
| CYRKYNDVSDLCKLE | 596 | Q8IXT1 | |
| LYCNICRSLFEKDKL | 2331 | Q6ZR08 | |
| NDERCSKKKLALCYT | 126 | P16581 | |
| KAYELSVLCDCEIAL | 31 | Q06413 | |
| KKATNAVDLYVCLLC | 301 | Q9UGL1 | |
| LDGCCKRRYLQKIEE | 161 | Q9UIX4 | |
| RCQVLYKTELSKEEC | 41 | P19883 | |
| KAVRQKEDCCFTILY | 86 | P16885 | |
| KAYELSVLCDCEIAL | 31 | Q02078 | |
| RYCCLNIKELEACKK | 51 | Q9H1M4 | |
| FSKLTLEQKELCRCR | 671 | A2RRP1 | |
| KAYELSVLCDCEIAL | 31 | Q02080 | |
| EHLCTYEKQICDKLA | 211 | Q9BXJ9 | |
| LITRDLVQEKYLECC | 241 | A6NCF6 | |
| CCYLKRESVELALKL | 186 | O43719 | |
| LYFSECNKCDDKKER | 26 | Q8IUC8 | |
| YKRCLKNENCSIVRI | 166 | P20393 | |
| LYFSECNKCDEKKER | 26 | Q10472 | |
| RECALLNLKLYCKEG | 3721 | Q9C0G6 | |
| ICKALEKDCRYSKGL | 181 | Q9Y6J0 | |
| TLKYREACKDLELAC | 1566 | P51587 | |
| CNLDDICKKYRSAYI | 161 | P56159 | |
| LFLLDQCEKYRRCKQ | 611 | Q6ZN84 | |
| YCNDVDRELRKCLKN | 36 | Q9NRP2 | |
| CLRKESDKECSVVIY | 1951 | O75417 | |
| PKCLKNEQYRILCDT | 46 | Q30KP9 | |
| SQELRKTFKEIICCY | 306 | P32245 | |
| LQEKLVSECATYKLC | 61 | P09919 | |
| LCLESVKNKYECEIQ | 126 | Q5PSV4 | |
| YEVKRLCKLKCQENT | 81 | Q96KX1 | |
| VECKLALLKYLCECQ | 116 | Q96T23 | |
| ISYELKACNPKLCRL | 126 | Q6UXV1 | |
| KAYELSVLCDCEIAL | 31 | Q14814 | |
| CYEKVCKETAEIRRQ | 126 | Q9BYC8 | |
| IYNLKDRLTAIKCCI | 2981 | Q8WXH0 | |
| CLKELERSYHLDKCQ | 996 | Q8IVG5 | |
| LIYDRCDLNCRIHKK | 171 | P37231 | |
| EKVSLYCDEVLQDCK | 121 | Q9BZQ2 | |
| KETYQSCLKSFECLL | 76 | Q9Y5N6 | |
| DVCRVVYQAKCSLIK | 206 | Q9BVR0 | |
| DCRLEENLTKKYCLE | 841 | Q4LDE5 | |
| IKCVLEDNKCSYFLS | 221 | Q15399 | |
| EECYSKLNVCSIAKR | 126 | P52823 | |
| RAVKKCTRYIDCDLN | 56 | P45381 | |
| INIEDLCLTKAAYCR | 86 | Q8N5K1 | |
| KNDAETLQKCLILCY | 551 | Q9BPX3 | |
| KLCRELYSKEQEHKC | 116 | Q5QGZ9 | |
| TKLEAKYLCSACRNV | 26 | Q12933 | |
| LIKCLEKEVAALCRY | 386 | P12956 | |
| DYIKQCSKCQEKLDR | 111 | O95625 | |
| CKVEVYLLELKLCEN | 131 | Q13107 | |
| KALEDVKANFYCELC | 46 | A4D1E1 | |
| EICYAECLLQKAALT | 236 | Q5VTQ0 | |
| VACVKKASYLDCIRA | 56 | P02787 | |
| DCKIIYLCRNAKDVA | 121 | P49888 | |
| ENDLKRLCDYVCDLL | 21 | O00743 | |
| YNKLTETCFLDCVKD | 21 | Q9Y5J7 | |
| HCKVEVYLTELKLCE | 126 | Q9Y4E8 | |
| LIYTCRDNKDCLIDK | 171 | P48443 | |
| SEEEKAKKLLYCSLC | 276 | Q569K4 | |
| ERCKNLDTEDTVYKC | 201 | Q9UJW7 | |
| QKLNSADRLYECKEC | 301 | Q8N141 | |
| CLYCEKTFRDKNTLK | 226 | Q9NRM2 | |
| LIREEKNSYKCEECG | 191 | Q08ER8 | |
| ALCCEIKKLKYEAET | 96 | Q2M389 | |
| EKLYECKECRKVFTQ | 276 | Q8TAQ5 | |
| LLKDVDTIFECKLCR | 61 | Q2TB10 | |
| KAVRPLELAYCLQKC | 116 | Q9UMW8 | |
| TREKLCEYKCEQTVR | 421 | Q8N859 | |
| RKIAYKNSLCDSCEK | 131 | P17014 | |
| QKLYKCALCLKEFRS | 1061 | Q2M1K9 | |
| CALCLKEFRSKQDLV | 1066 | Q2M1K9 | |
| DKRYKCSLCEKTFIN | 211 | O60765 | |
| QECKICRKIIYLNTD | 121 | Q2M3X9 | |
| NFTLCYIKETEKDCL | 421 | P08575 | |
| KDELLCSICLSIYQD | 6 | Q9BVG3 | |
| NKVRAYLICCKLRSA | 2471 | Q68DK2 | |
| KCTLQDCLRLFSKEE | 961 | P40818 | |
| DIDKNEKCYLCKSLV | 556 | Q96RL1 | |
| KYQLLLKELLTCCEE | 1431 | O75962 | |
| KLQYLEKEARVCVVC | 786 | Q7Z3T8 | |
| KVIHTREKLYKCEEC | 591 | A6NN14 | |
| IHTREKLYKCEECVK | 761 | A6NN14 | |
| KLIHTREKLYKCEEC | 1011 | A6NN14 | |
| REKLYKCEECVKAFN | 1016 | A6NN14 | |
| EDLSECLIKNCLVYS | 336 | O43264 | |
| YTNECQLCLARIKTK | 61 | O60575 | |
| ALDESCEDKNRYICK | 161 | Q13241 | |
| NLKYLCLEKCNLSAA | 811 | Q86W25 |